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LETTER TO THE EDITORStatins-based prophylactic
mouthwash and nasal spray may
protect against coronavirus disease
2019S. Abdulrab1,2, B. Alkadasi3, S. Al-maweri4, E. Halboub5,6,
H. Alhadainy7 and G. Geerts2
1) Madinat Khalifa Health Centre, Primary Health Care Corporation, Doha,
Qatar, 2) Department of Restorative Dentistry, Faculty of Dentistry, University
of the Western Cape, Cape Town, South Africa, 3) Department of
Periodontology and Oral Medicine, Faculty of Dentistry, Ibb University, Ibb,
Yemen, 4) Department of Oral Medicine and Diagnostic Science, Al Farabi
Colleges, Riyadh, 5) Department of Maxillofacial Surgery and Diagnostic
Sciences, College of Dentistry, Jazan University, Saudi Arabia, 6) Department
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Sana’a University, Sana’a, Yemen and 7) Department of Endodontics, College
of Dentistry, Tanta University, EgyptAbstractThe novel coronavirus 2019 (COVID-19) pandemic, caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused
an unprecedented healthcare crisis. SARS-CoV-2 gets access into the
human body mainly through the nose and the mouth and invades
these mucosae in its destination to the pulmonary tissues. Thus, the
oral and nasal mucosae serve as the main routes and reservoirs for
aerosolized transmission of the viral particles to the external
environment and hence infection transmission. Statins have been
shown to have antimicrobial, antiviral, antifungal, anti-inflammatory,
immunomodulatory, and antioxidant properties. Therefore, we
hypothesize that using statins-based prophylactic mouthwashes will
reduce COVID-19 transmission in dental settings.
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The novel coronavirus disease 2019 (COVID-19) pandemic,
caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has caused an unprecedented health-care crisis.
By the date of writing this report, the pandemic has affected
more than 20 million people and caused more than 740 000
associated deaths worldwide. SARS-CoV-2 gets access into the
human body mainly through the nose and, to a lesser extent,
through the mouth. The virus invades the nasal and oral
mucosal cells, mainly through angiotensin-converting enzyme 2
(ACE2) receptors. In the following days, the virus progresses
down through the pulmonary system triggering mostly mild
respiratory symptoms, but it may trigger an intense inflamma-
tory host response, sometimes leading to a life-threatening
acute respiratory distress syndrome, in a fraction of in-
dividuals [1]. It is obvious by now that SARS-CoV-2 resides in
the nasal and oral mucosal cells [1], rendering these anatomical
areas sources of seeding the lower airways causing progression
of pulmonary disease; and serving as the main routes and res-
ervoirs for aerosolized transmission of the viral particles to the
external environment [2]. Health-care workers, especially
dentists and otolaryngologists, are at highest risk of becoming
infected through droplet transmission or direct contact. In
addition, WHO states that airborne transmission may be
possible in specific circumstances and settings in which pro-
cedures that generate aerosols are performed. In dental set-
tings, any dental procedure that can aerosolize contaminated
saliva can significantly increase airborne contamination with
microorganisms. All dental procedures involving the use of
hand-pieces and air–water syringes produce aerosols and
splatter, resulting in exposure of the clinicians, dental assistants
and patients to a higher risk of being infected, and/or rendering
them sources of infection transmission. We hypothesize that
using a statins-based prophylactic mouthwash will reduce
COVID-19 transmission in dental settings.
The statin family of drugs represent safe and effective
therapeutic agents, indicated mainly to reduce cholesterol
biosynthesis in the liver, and hence the levels of low-
density lipoprotein cholesterol [3]. Apart from this main
pharmacological property, statins have been shown to have
antimicrobial, antiviral, antifungal, anti-inflammatory, immu-
nomodulatory and antioxidant properties [4]. More specif-
ically, several studies showed that statins inhibit Zika, Ebola,
dengue and influenza viruses and cytomegalovirus [4,5].
There are many mechanisms (pathways) that may explain
the antiviral property of statins. First, statins reduce serum
cholesterol levels that facilitate binding of some viruses to
the host cells result in lower viral titres. In fact, research
showed that some viruses bind to the lipid rafts (rich inNew Microbe and New Infect 2020; 37: 100751
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lipid rafts, which constitute important pockets for virus
replication [6]. Third, statins have been shown to interfere
with ACE2 signalling and to promote ACE2 up-regulation,
so reversing the action of SARS-CoV-2 [7].
A recent report based on molecular docking analysis showed
that statins might inhibit SARS-CoV-2 entry into host cells
through direct binding to its main protease [8]. Moreover, a
more recent study, demonstrated that in-hospital systemic use
of statins is associated with a reduced risk of mortality among
individuals with COVID-19 [9].
From a dental perspective, several in vitro studies showed
promising antibacterial effects of statins against periodontal
pathogens [10,11]. One meta-analysis indicated that statins
significantly improved periodontal parameters when used as
sole adjuncts to mechanical periodontal treatment [12].
Recently, one study demonstrated a significant reduction in
periodontal parameters and inflammatory biomarkers with the
use of simvastatin gel and mouthwash in a 1% preparation [13].
It has been argued that the viral load in the oropharynx and
nasopharynx with SARS-CoV-2 infection is as high in asymp-
tomatic individuals as in those with symptoms [2]. Assuming
that many asymptomatic and even symptomatic people may
seek dental treatment, it is imperative to reduce the viral load in
the oropharynx through adequate oral prophylactic measures
to eliminate, or at least to minimize, the risk of SARS-CoV-2
transmission to dental personnel and patients.
To achieve this, we suggest: (a) pre-procedural use of
mouthwashes and nasal sprays by dental patients, to reduce the
risk that any aerosol-generating procedures will infect health-
care workers, and (b) use of mouthwashes and nasal sprays by
health-care workers pre- and post-exposure to patients with
confirmed or suspected infection to reduce the risk of infection
through their mouth or nose. We suggest the following formu-
lation in the context of the currently discussed hypothesis:
preparation of 1% simvastatin mouthwash by dissolving 20 mg
simvastatin tablets in distilled water. Sodium benzoate is added as
a preservative, followed by glycerin and natural food colour and
flavour so that its taste will be tolerated. The final preparation
will then be adjusted for pH by adding triethanolamine solution
[13]. When considering use of a statins mouthwash, the sug-
gested application time is 15–20 seconds [14].
Given the potential antiviral effect of statins, we hypothesize
that the use of topical statins as a mouthwash or even as a nasal
spray may minimize the risk of SARS-CoV-2 transmission in
dental settings, and so will protect patients and health-care© 2020 The Author(s). Published by Elsevier Ltd, NMNI, 37, 100751
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceproviders during the COVID-19 pandemic. Clinical trials
should be considered for this hypothesis.
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